BMC Nephrology · 2022 · 22 citations · 25 references
MedicineInternal MedicineNephrologyDialysisHemodialysisRenal Replacement TherapyCardiovascular DiseaseChronic HemodialysisChronic Kidney DiseaseMaintenance HemodialysisRenal DiseaseCardiovascular Disease MortalityCardiovascular Outcomes In HemodialysisCardiovascular Risk In HemodialysisContinuous HemodialysisCox RegressionProspective Cohort DataRestricted Cubic Spline Models
BACKGROUND: The association between serum total indoxyl sulfate (tIS), and cardiovascular disease (CVD) and all-cause mortality is a matter of debate. In the current study we sought to determine the association, if any, between serum tIS, and all-cause and CVD-associated mortality in patients on maintenance hemodialysis (MHD). METHODS: A prospective cohort study was conducted involving 500 MHD patients at Dalian Municipal Central Hospital from 31 December 2014 to 31 December 2020. Serum tIS levels were measured at baseline and classified as high (≥44.16 ng/ml) or low (< 44.16 ng/ml) according to the "X-tile" program. Besides, the associations between continuous serum tIS and outcomes were also explored. Predictors were tested for colinearity using variance inflation factor analysis. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated using Cox proportional hazards regression models. Restricted cubic spline model was performed to assess dose-response relationships between tIS concentration and all-cause and CVD mortality. RESULTS: During a 58-month median follow-up period, 224 deaths (132 CVD deaths) were documented. After adjustment for potential confounders, the serum tIS level was positively associated with all-cause mortality (HR = 1.02, 95% = 1.01-1.03); however, we did not detect a significant association when tIS was a dichotomous variable. Compared with the MHD population with a serum tIS level < 44.16 ng/ml, the adjusted HR for CVD mortality among those with a serum tIS level ≥ 44.16 ng/ml was 1.76 (95% = 1.10-2.82). Furthermore, we also noted the same association when the serum tIS level was a continuous variable. CONCLUSION: The serum tIS level was associated with higher risk of all-cause and CVD mortality among MHD patients. Further prospective large-scale studies are required to confirm this finding.
25
Robert L. Camp, Marisa Dolled‐Filhart, David L. Rimm · Clinical Cancer Research · 2004 · 3.9K citations
Medicine, Biostatistics, Oncology +17
Fellype Carvalho Barreto, Daniela Veit Barreto, Sophie Liabeuf et al. · Clinical Journal of the American Society of Nephrology · 2009 · 905 citations · Full text
Medicine, Biochemistry, Nephrology +15